SynthesisFrontiers in medicine2026
Comparison of common pharmacological strategies for post-photorefractive keratectomy pain management: a systematic review and network meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically evaluate the comparative efficacy and safety of common pharmacological strategies for managing post-photorefractive keratectomy (PRK) eye pain through a network meta-analysis, providing evidence-based guidance for clinical medication. Methods: Randomized controlled trials (RCTs) were systematically retrieved from Cochrane Library, Web of Science, PubMed, and EMbase (from inception to November 15, 2025). Using R Studio, we conducted a network meta-analysis to assess differences in Visual Analogue Scale (VAS) scores and adverse events across pharmacological interventions. SUCRA (Surface Under the Cumulative Ranking) values were calculated to determine the relative ranking of interventions, while accounting for heterogeneities in administration timing and dosage. Results: A total of 28 studies were included, involving 2,797 patients. In route-stratified analyses, Ofloxacin (SUCRA = 0.84) and Proparacaine (0.76) were the top-ranked topical agents for analgesia, while Codeine combined with Acetaminophen (0.71) ranked highest among systemic agents. The exploratory combined network yielded identical top-three rankings, though these cross-route comparisons are susceptible to transitivity violations. Notably, effect sizes for most interventions relative to placebo spanned the line of no effect. Regarding safety, Diclofenac (SUCRA = 0.81), Ketorolac (0.70), and Nepafenac (0.53) demonstrated the optimal profiles. The highest numbers of adverse events occurred with Pregabalin (39 cases), Fentanyl (20 cases), and Codeine combined with Acetaminophen (13 cases); however, safety conclusions remain limited as only seven studies reported highly heterogeneous adverse event data. Conclusion: Ofloxacin demonstrates superior relative efficacy for pain control following PRK, while Diclofenac offers the most favorable safety profile. Clinicians should synthesize these comparative findings with individual patient profiles to optimize drug selection, ensuring a balanced approach between effective pain relief and minimized adverse risks. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251238092, CRD420251238092.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.